tiprankstipranks
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
US Market
LYEL
Lyell Immunopharma
RESEARCH TOOLSreports

Lyell Immunopharma (LYEL) Financial Statements

153 Followers

Lyell Immunopharma Financial Overview

Lyell Immunopharma's market cap is currently $533.97M. The company's EPS TTM is $-7.18; its P/E ratio is -1.92; Lyell Immunopharma is scheduled to report earnings on March 12, 2026, and the estimated EPS forecast is $-2.31. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 36.00K$ 61.00K$ 130.00K$ 84.68M$ 10.65M
Gross Profit$ -11.50M$ 61.00K$ 130.00K$ 84.68M$ 10.65M
Operating Income$ -203.77M$ -358.75M$ -247.01M$ -187.06M$ -214.78M
EBITDA$ -192.24M$ -200.64M$ -226.76M$ -169.04M$ -201.15M
Net Income$ -274.45M$ -342.99M$ -234.63M$ -183.12M$ -250.22M
Balance Sheet
Cash & Short-Term Investments$ 247.22M$ 370.53M$ 546.22M$ 640.15M$ 614.79M
Total Assets$ 340.05M$ 490.86M$ 750.03M$ 937.56M$ 1.13B
Total Debt$ 41.92M$ 58.97M$ 63.17M$ 67.70M$ 67.82M
Net Debt$ -18.26M$ -46.63M$ -82.48M$ -55.85M$ -226.01M
Total Liabilities$ 91.85M$ 108.03M$ 95.08M$ 104.31M$ 197.62M
Stockholders' Equity$ 248.20M$ 382.82M$ 654.95M$ 833.25M$ 929.79M
Cash Flow
Free Cash Flow$ -150.80M$ -162.86M$ -166.38M$ -193.83M$ -191.75M
Operating Cash Flow$ -150.02M$ -162.39M$ -163.69M$ -169.56M$ -126.25M
Investing Cash Flow$ 54.10M$ 122.42M$ 184.05M$ -11.54M$ -121.57M
Financing Cash Flow$ 50.41M$ 1.33M$ 1.74M$ 10.63M$ 401.24M
Currency in USD

Lyell Immunopharma Earnings and Revenue History

Income Statement >

Lyell Immunopharma Debt to Assets

Balance Sheet >

Lyell Immunopharma Cash Flow

Cash Flow >

Lyell Immunopharma Forecast EPS vs Actual EPS

Earnings >